This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Hold on to ResMed (RMD) Stock for Now
by Zacks Equity Research
ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.
STERIS (STE) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
STERIS (STE) witnesses solid revenue growth across each of its operating segments in the reported quarter.
ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
by Zacks Equity Research
ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.
Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid
by Zacks Equity Research
Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.
Masimo (MASI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 5.33% and 3.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Masimo Gets CE Mark for ANI Module, Enhances Root Platform
by Zacks Equity Research
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Masimo (MASI) Reports Next Week: What Awaits?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical (ISRG) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) Q1 results outside the United States impress.
Stryker's LIFEPAK CR2 Defibrillator Launch to Boost MedSurg
by Zacks Equity Research
Stryker's (SYK) emergency care department offers a broad range of products and systems.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) has been benefitting from developments like the FDA clearance of the Rad-67 Pulse CO-Oximeter.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Management at Accuray (ARAY) sees significant opportunities in China.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
Align Rides on Firm Global Footprint Despite Fierce Rivalry
by Zacks Equity Research
Align's (ALGN) solid performance in the Europe, Middle East and Africa and Asia-Pacific geographies is appreciative.
Here's Why You Should Hold Becton, Dickinson Stock for Now
by Zacks Equity Research
Becton, Dickinson (BDX) announces the FDA premarket approval for Venovo venous stent device.
ABIOMED Impella Data Show Significant Rise in Survival Rates
by Zacks Equity Research
ABIOMED (ABMD) plans to expand products like Impella CP, Impella Connect, Impella 5.5 and Impella RP.
Varian Medical Opens Office in South Africa, Expands in EMEA
by Zacks Equity Research
Varian Medical (VAR) sees a slew of developments in the EMEA region of late.
Here's Why You Should Retain ABIOMED Stock in Your Portfolio
by Zacks Equity Research
Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.
Integer Holdings Gets Positive Outlook & B+ Rating From S&P
by Zacks Equity Research
Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.
Why Veeva Systems (VEEV) is an Attractive Pick Right Now?
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.
Here's Why Investors Should Retain NextGen Healthcare Stock
by Zacks Equity Research
Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.
Why Is Masimo (MASI) Up 2.5% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts' FollowMyHealth Partners Ephraim McDowell Health
by Zacks Equity Research
Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.
Fresenius Medical to Make Huge Investments, Competition Rife
by Zacks Equity Research
Fresenius Medical (FMS) is likely to make huge investments in India and China.
Masimo Gets FDA Clearance for Rad-67 Monitoring Device
by Zacks Equity Research
The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.